Pemetrexed News and Research

RSS
New combination therapy found to be well tolerated in patients with aggressive brain tumor

New combination therapy found to be well tolerated in patients with aggressive brain tumor

Patients with stage IV disease now living a median 6.8 years after ALK+ NSCLC diagnosis

Patients with stage IV disease now living a median 6.8 years after ALK+ NSCLC diagnosis

Toxic effects of drugs in the lungs 'more widespread than thought'

Toxic effects of drugs in the lungs 'more widespread than thought'

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Neon Therapeutics evaluates safety, efficacy of NEO-PV-01 in combination with KEYTRUDA and chemotherapy

Neon Therapeutics evaluates safety, efficacy of NEO-PV-01 in combination with KEYTRUDA and chemotherapy

Combination immunotherapy as second or third line treatment of mesothelioma shows promising results

Combination immunotherapy as second or third line treatment of mesothelioma shows promising results

FDA approves expanded use of Zykadia for first-line treatment of ALK-positive metastatic NSCLC

FDA approves expanded use of Zykadia for first-line treatment of ALK-positive metastatic NSCLC

Melanoma drug offers considerable added benefit for patients with advanced NSCLC

Melanoma drug offers considerable added benefit for patients with advanced NSCLC

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

First-line nivolumab promising in advanced NSCLC

First-line nivolumab promising in advanced NSCLC

Novel combination therapy slows cancer growth in patients with advanced solid tumors

Novel combination therapy slows cancer growth in patients with advanced solid tumors

Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

Bevacizumab extends survival of pleural mesothelioma patients

Bevacizumab extends survival of pleural mesothelioma patients

VCU Massey Cancer Center scientists reveal signaling process that leads to excessive growth of cancer

VCU Massey Cancer Center scientists reveal signaling process that leads to excessive growth of cancer